Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cortisone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 1.00 |
| ▸ | FNTA | P49354 | 5/20 | 1.00 |
| ▸ | FNTB | P49356 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.78 |
| ▸ | SERPINA6 | P08185 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | SHBG | P04278 | 2/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.78 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortisone Acetate SCHEMBL9819561 | 1.00 | FNTA (1.00) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL10301195 | 1.00 | FNTA (1.00) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL9819556 | 1.00 | FNTA (1.00) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL3403149 | 0.89 | FNTA (0.86) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL19463054 | 0.89 | HIF1A (0.81) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone Acetate SCHEMBL19463056 | 0.89 | HIF1A (0.81) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL25774026 | 0.89 | FNTA (0.80) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL21790153 | 0.88 | FNTA (0.82) | FNTAFNTBNR3C1TSHRKMT2A | |
| SCHEMBL19644910 | 0.88 | FNTA (0.79) | FNTAFNTBNR3C1TSHRKMT2A | |
| Cortisone SCHEMBL6535496 | 0.88 | HSD17B10 (1.00) | FNTAFNTBNR3C1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17065 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3125943-B1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260091052-A1 | MICRORNA AND USES THEREOF IN PREVENTION AND/OR TREATMENT OF FIBROPLASIA MEDICAL SIGN AND/OR SYNDROME | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-04-02 | — | — | US | claimed |
| US-12528874-B2 | Methods and compositions for treating systemic lupus erythematosus (SLE) with mosunetuzumab | GENENTECH, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4615513-A1 | BISECTING-GLYCAN BRIDGED CONJUGATION FOR PRODUCING GLYCOPROTEIN CONJUGATES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | claimed |
| EP-3829569-B1 | SPINOSYN FORMULATIONS FOR USE IN THE TREATMENT OF DEMODEX-INDUCED OCULAR CONDITIONS | APERTA BIOSCIENCES LLC (US) | 2025-09-03 | — | — | EP | claimed |
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| CN-120154586-A | Powder aerosol composition for inhalation, powder aerosol for inhalation, preparation method of powder aerosol for inhalation and powder aerosol for inhalation | 上海臣邦医药科技股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| EP-0343268-A1 | Pharmaceutical composition and process for preparing the same | BIOGAL GYOGYSZERGYAR (HU) | 1989-11-29 | — | — | EP | claimed |
| US-4867985-A | CONTROLLED RELEASE OF NON-STEROID ANTIINFLAMMATORY AGENTS | EUROCELTIQUE S.A. (LU) | 1989-09-19 | — | — | US | claimed |
| EP-0209403-A2 | Process for preparing ultrafine particles of organic compounds | Research Development Corporation of Japan (JP) | 1987-01-21 | — | — | EP | claimed |
| US-4563351-A | SUSTAINED RELEASE | FORSYTH DENTAL INFIRMARY FOR CHILDREN (US) | 1986-01-07 | — | — | US | claimed |
| US-4540602-A | Process for the preparation of activated pharmaceutical compositions | FREUND INDUSTRY COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | claimed |
| EP-0147780-A2 | Drug delivery device | MERCK & CO. INC. (US) | 1985-07-10 | — | — | EP | claimed |
| EP-0129893-A2 | Ground mixture | Takeda Chemical Industries, Ltd. (JP) | 1985-01-02 | — | — | EP | claimed |
| US-4317816-A | TREATMENT WITH GLUCOCORTICOID AND SAPOININ OF GINSENG | OSAKA CHEMICAL LABORATORY CO., LTD. (JP) | 1982-03-02 | — | — | US | claimed |
| US-3962430-A | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | claimed |
| US-3960757-A | HYDROPHOBIC | TOYO JOZO CO., LTD. (JA) | 1976-06-01 | — | — | US | claimed |